| 产品描述: | EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain |
| 靶点: |
Epoxide Hydrolase;EpoxideHydrolase |
| 体内研究: |
EC5026 (BPN-19186) has already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses |
| 参考文献: |
1. EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.467 ml |
12.334 ml |
24.668 ml |
| 5 mM |
0.493 ml |
2.467 ml |
4.934 ml |
| 10 mM |
0.247 ml |
1.233 ml |
2.467 ml |
| 50 mM |
0.049 ml |
0.247 ml |
0.493 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |